Pluri Inc. generated $1.016 million in Revenue for the year ended June 30, 2026, while reporting a $25.369 million net loss and a $2.44 basic and diluted loss per share. Revenue declined from $1.336 million as lower project activity affected CDMO services and FoodTech collaborations, while Research and Development spending increased 17%.
Key Highlights
- Research and development expenses, net, climbed 17% to $15.092 million for the year ended June 30, 2026.
- General and administrative expenses rose 3% to $10.299 million from $9.979 million.
- Pluri identified Patent approval uncertainty and possible infringement of patents issued to others as principal risks.
Pluri Inc. (NASDAQ: PLUR) reported $1.016 million in revenue for the year ended June 30, 2026, down from $1.336 million in the preceding year. The company recorded a $25.369 million net loss, compared with a $23.250 million net loss previously, while basic and diluted loss per share was $2.44. Lower project activity affected revenue from CDMO services and FoodTech proof-of-concept collaborations.
Full-Year Results In Detail
Gross profit was $453,000, versus $654,000 in the preceding year. Research and development expenses, net, increased 17% from $12.851 million to $15.092 million. General and administrative expenses rose 3% from $9.979 million to $10.299 million. Operating loss was $24.938 million, compared with $22.176 million in the prior year. Other financial income, net, was $476,000, compared with other financial expenses, net, of $206,000 in the preceding year. Interest expense was $932,000, compared with $873,000.
Spending And Operating Drivers
The company said the reduction in revenue was primarily tied to lower project activity across the reported operating areas. The same activity level also reduced cost of revenues during the year. Research and development spending reflected higher salaries and related expenses, including foreign-exchange differences and new employees added after the Acquisition of Kokomodo. Those increases were partly offset by headcount reductions connected with a cost-reduction plan. Facility Lease expenses increased, mainly because of Ever After Foods’ new operating facility. Share-based compensation also rose in connection with Options granted to an Ever After Foods employee. Lower participation by NIAID and reduced research and development expenses following proof-of-concept activities at subsidiaries partly offset those increases. General and administrative costs included higher share-based compensation tied to restricted shares, restricted stock units and options granted during the reporting period.
Balance Sheet And Funding Items
Total liabilities and Deficit stood at $24.878 million at June 30, 2026, compared with $38.683 million at June 30, 2025. Cash and deposits of $1.047 million were pledged by Pluri Biotech and Ever After Foods to secure Credit lines, lease agreements and bank guarantees. A $1,250 advance was received from Chutzpah Holdings LP under an advance subscription agreement.
Patent Risks Remain
Pluri said pending patent applications may not result in issued patents. It also identified the possibility that its activities could infringe patents issued to other parties. The company’s patent portfolio includes applications and granted rights covering cell expansion, adherent cells from placenta tissue, inflammatory colon disease treatment, cell selection for transplantation, cell harvesting and related therapeutic uses. Listed expiry dates extend from 2027 through 2035.



Please wait processing your request...